Question

Difficulty: MediumPediatric Respiratory Disorders

A mother brings her 7-month-old female infant to the pediatrician's office in early November for a routine well-child evaluation. The infant was born prematurely at 28 weeks of gestation. Her neonatal course was complicated by respiratory distress syndrome, requiring mechanical ventilation and exogenous surfactant administration. She was successfully extubated and eventually discharged home at 36 weeks corrected gestational age without the need for supplemental oxygen. The mother reports that the infant is feeding well, gaining weight, and has not been hospitalized since birth. Vital signs are temperature 37.1°C (98.8°F), heart rate 120/min, and respiratory rate 30/min. Physical examination reveals a healthy-appearing infant with clear breath sounds bilaterally and no cardiac murmurs. The mother expresses concern about the upcoming winter season and asks what can be done to protect her child's lungs from severe viral infections. Assuming all routine immunizations for her age are up to date, which of the following is the most appropriate additional pharmacological intervention for this patient?

  1. Administration of palivizumabAnswer
  2. B
    Initiation of daily inhaled fluticasone
  3. C
    Prescription for as-needed nebulized albuterol
  4. D
    Prescription for prophylactic oral amoxicillin
  5. E
    Administration of the live-attenuated influenza vaccine

Answer

Administration of palivizumab
The correct answer is the administration of palivizumab. Palivizumab is a monoclonal antibody directed against the fusion (F) protein of the Respiratory Syncytial Virus (RSV). It provides passive immunity and is indicated for the prevention of severe lower respiratory tract RSV disease in specific high-risk pediatric populations. The American Academy of Pediatrics (AAP) guidelines recommend palivizumab for infants born before 29 weeks of gestation who are younger than 12 months at the start of the RSV season. Other indications include infants with hemodynamically significant congenital heart disease and infants with chronic lung disease of prematurity (bronchopulmonary dysplasia) who required medical therapy within 6 months of the RSV season. Because this infant was born at 28 weeks of gestation and is 7 months old entering her first RSV season in November, she strictly meets the criteria for palivizumab administration.

Step-by-Step Solution

1
Identify the patient's major risk factors.
The patient is a 7-month-old infant who was born prematurely at 28 weeks of gestation.
Gestational age at birth and current chronological age are the primary determinants for specific prophylactic interventions in pediatrics.
2
Recognize the seasonal and environmental context.
The visit is in early November, marking the beginning of the typical winter respiratory virus season (including Respiratory Syncytial Virus).
Certain prophylactic medications are only administered during specific times of the year when the risk of exposure is highest.
3
Determine the appropriate prophylactic intervention based on guidelines.
Infants born before 29 weeks of gestation who are younger than 12 months at the start of the RSV season qualify for palivizumab.
Palivizumab provides passive immunity against RSV, significantly reducing the risk of severe lower respiratory tract disease in high-risk infants.

Key Concept

Indications for Respiratory Syncytial Virus (RSV) prophylaxis with palivizumab in high-risk pediatric populations.
Estimated Time:1m 15s
Rate this question